Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells

E. Giovannetti; M. Labots; H. Dekker; E. Galvani; J.S.W. Lind; R. Sciarrillo; R.J. Honeywell; E.F. Smit; H.M. Verheul; G.J. Peters

doi:10.2174/138161213804547268

Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells

E. Giovannetti, M. Labots, H. Dekker, E. Galvani, J.S.W. Lind, R. Sciarrillo, R.J. Honeywell, E.F. Smit, H.M. Verheul, G.J. Peters

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	927-939
Journal	Current Pharmaceutical Design
Volume	19
Issue number	5
DOIs	https://doi.org/10.2174/138161213804547268
Publication status	Published - 2013

Access to Document

10.2174/138161213804547268

Cite this

Giovannetti, E., Labots, M., Dekker, H., Galvani, E., Lind, J. S. W., Sciarrillo, R., Honeywell, R. J., Smit, E. F., Verheul, H. M., & Peters, G. J. (2013). Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells. Current Pharmaceutical Design, 19(5), 927-939. https://doi.org/10.2174/138161213804547268

Giovannetti, E. ; Labots, M. ; Dekker, H. ; Galvani, E. ; Lind, J.S.W. ; Sciarrillo, R. ; Honeywell, R.J. ; Smit, E.F. ; Verheul, H.M. ; Peters, G.J. / Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells. In: Current Pharmaceutical Design. 2013 ; Vol. 19, No. 5. pp. 927-939.

@article{b3e7ddd5e0e649239af12408dd502cc4,

title = "Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells",

author = "E. Giovannetti and M. Labots and H. Dekker and E. Galvani and J.S.W. Lind and R. Sciarrillo and R.J. Honeywell and E.F. Smit and H.M. Verheul and G.J. Peters",

year = "2013",

doi = "10.2174/138161213804547268",

language = "Undefined/Unknown",

volume = "19",

pages = "927--939",

journal = "Current Pharmaceutical Design",

issn = "1381-6128",

publisher = "Bentham Science Publishers B.V.",

number = "5",

}

Giovannetti, E , Labots, M, Dekker, H, Galvani, E, Lind, JSW, Sciarrillo, R, Honeywell, RJ , Smit, EF , Verheul, HM & Peters, GJ 2013, 'Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells', Current Pharmaceutical Design, vol. 19, no. 5, pp. 927-939. https://doi.org/10.2174/138161213804547268

Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells. / Giovannetti, E.; Labots, M.; Dekker, H.; Galvani, E.; Lind, J.S.W.; Sciarrillo, R.; Honeywell, R.J.; Smit, E.F.; Verheul, H.M.; Peters, G.J.

In: Current Pharmaceutical Design, Vol. 19, No. 5, 2013, p. 927-939.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells

AU - Giovannetti, E.

AU - Labots, M.

AU - Dekker, H.

AU - Galvani, E.

AU - Lind, J.S.W.

AU - Sciarrillo, R.

AU - Honeywell, R.J.

AU - Smit, E.F.

AU - Verheul, H.M.

AU - Peters, G.J.

PY - 2013

Y1 - 2013

U2 - 10.2174/138161213804547268

DO - 10.2174/138161213804547268

M3 - Article

VL - 19

SP - 927

EP - 939

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 5

ER -